NeuroThera Labs Inc., a clinical-stage biotech company, has closed the final tranche of its non-brokered private placement, raising C$2.7 million by selling 22.5 million units at C$0.12 each. Each unit includes one common share and one warrant exercisable until August 2029. The funds will be used for general working capital and corporate expenses. The offering awaits final approval from the TSX Venture Exchange, and SciSparc Ltd., the majority owner, participated fully in this tranche.
Jefferies downgraded Home Depot from Buy to Hold due to worries over minimal profit growth despite expected revenue rise in Q2. Customer transactions have declined for five quarters, indicating growth relies on bigger purchases, not more customers. M...
Historical data suggests that a $10,000 investment in the QQQ ETF could increase to approximately $66,000 over a decade. This highlights the potential long-term growth of technology-focused investments. Investors might consider this when planning the...
Fabrinet reported quarterly earnings with an EPS of $4.10 and revenue of $1.32 billion, exceeding analyst expectations and marking a 45% increase in revenue year-over-year. The company specializes in optical packaging and manufacturing for high-growt...
Polygon Labs has entered Phase 2 of the Bank of England's Digital Pound Lab, collaborating with NOBO Finance and Dun & Bradstreet to explore near-instant cross-border settlements and portable credit identities using Polygon's Open Money Stack technol...
Nano-X Imaging Ltd. is set to report its Q3 earnings with analysts expecting a loss of $0.16 per share and revenues of $5.38 million. The company is currently dealing with multiple class-action lawsuits alleging securities law violations, which adds ...
